The FDA has introduced draft guidance to minimize the use of animal testing in the development of cancer drugs. In other news, former U.S. Attorney General Pam Bondi has revealed she is battling thyroid cancer. Concerns are rising that new work requirements for Medicaid could lead to a significant decrease in cancer screenings. A groundbreaking test for circulating tumor DNA has shown promise in identifying breast cancer recurrence over a year before it is detectable through traditional methods. The increasing use of AI in radiology is raising alarms about potential threats to patient privacy. In a collective appeal, 60 organizations have urged the protection of the U.S. Preventive Services Task Force’s integrity following leadership changes under the previous administration. A cybersecurity breach at The Oncology Institute has compromised patient data. Researchers are exploring whether bioengineered chewing gum could play a role in preventing head and neck cancers. There is also debate over the oral breast cancer drug camizestrant, as the FDA’s advisory committee has rejected it, while the European Medicines Agency has recommended its approval. AstraZeneca announced that the FDA will delay its decision on camizestrant as it reviews additional data.
Is the FDA Rethinking Animal Testing, AI Privacy Risks, and Cancer-Fighting Chewing Gum?
